Some cancer drugs buy patients only a few extra weeks of life, while others cut the risk of death nearly in half — and the gap between those two outcomes is bigger than most patients realize when they sign a consent form.
Quick Take
- Older chemotherapy regimens for advanced cancer added a median of just 9 weeks of survival compared with no treatment.
- Federal regulators often approve cancer drugs using tumor shrinkage or progression delays, not proof of longer life.
- Newer combination therapies, including Keytruda, Opdivo, and Tecentriq, have posted measurable survival gains in large trials.
- Not every new drug works — a 2026 Pfizer lung cancer trial failed to beat chemotherapy on survival.
The Weeks-Not-Years Problem With Older Chemotherapy
A landmark review of randomized trials in advanced non-small-cell lung cancer found patients given cisplatin-based chemotherapy lived a median of 8.0 months. Patients who got supportive care alone lived 5.7 months. That’s a difference of 9 weeks, though the survival curves showed a real, statistically significant benefit. For decades, this was the honest baseline skeptics pointed to when they questioned whether chemo’s costs and side effects were worth it.
Why Regulators Lean on Surrogate Endpoints
Most new cancer drugs don’t reach the market by proving patients live longer. They get approved because a tumor shrinks or stops growing for a while, a substitute measure called a surrogate endpoint. Researchers reviewing 194 cancer drug approvals found the majority relied on these stand-ins rather than confirmed survival or quality-of-life gains. The Food and Drug Administration allows this shortcut when a surrogate is “reasonably likely” to predict real benefit, a lower bar than proof.
That system speeds drugs to desperate patients faster. It also means some approved treatments never get confirmed to extend life at all, and a few get pulled later once follow-up studies come up short. Skeptics of the pharmaceutical approval pipeline have a fair point: faster is not always better when the confirming evidence lags years behind the marketing.
New Combination Drugs Are Posting Real Survival Gains
The newest generation of cancer drugs tells a different story than the old chemo-alone data. Merck’s Keytruda, paired with chemotherapy, cut the risk of death by 44 percent compared with chemotherapy alone in a pooled analysis of advanced lung cancer patients. In gastric cancer, the same combination pushed median survival from 11.5 months to 12.9 months.
Bristol Myers Squibb’s Opdivo, added to chemotherapy before lung cancer surgery, nearly doubled median event-free survival, from 20.8 months to 31.6 months. Roche’s Tecentriq combination extended survival in small cell lung cancer from 10.3 months to 12.3 months, a gap regulators called clinically meaningful. These are not surrogate measures. They are actual survival numbers pulled straight from company trial data.
Not Every New Drug Delivers
The record isn’t uniformly good news, and that matters for anyone skeptical of drug-industry hype. An experimental pancreatic cancer drug from Actuate Therapeutics reportedly doubled the share of patients alive at one year and cut death risk by 38 percent in early trial results. Meanwhile, Pfizer’s sigvotatug vedotin failed to beat plain chemotherapy on overall survival in a 2026 lung cancer trial, a reminder that promising drugs regularly wash out in late-stage testing.
That split outcome is the honest picture. Some combination therapies are genuinely moving survival numbers in the right direction. Others, despite years of investment and hopeful headlines, simply don’t work once tested against a real comparison group.
If you put together all the new chemotherapy drugs approved over a dozen years, the average overall survival benefit is only 2.1 months. https://t.co/nJHpcO1i5O pic.twitter.com/X5QIty9TxU
— Michael Greger, M.D. (@nutrition_facts) September 29, 2026
What This Means for Patients and Families
Patients and families weighing chemotherapy deserve a clear-eyed answer, not a marketing pitch. Ask whether a drug’s approval rested on tumor shrinkage or on confirmed survival data. Ask how many months of median survival gain a trial actually measured, and against what comparison. The data exists. It just takes some digging past the press release to find whether a drug adds weeks, months, or something that genuinely changes the odds.
Sources:
nutritionfacts.org, fda.gov, academic.oup.com, thelancet.com, aacr.org, reuters.com, merck.com, prnewswire.com
